2025年11月10日起，我国在现行国家免疫规划疫苗基础上，将HPV疫苗纳入国家免疫规划。此前，本市 以落实2025年民生实事项目的方式，为2025年9月新入学的初一在校女生免费接种HPV疫苗。针对两项 政策如何衔接的问题，市疾控局表示，2025年9月新入学的初一在校女生，如已接种本市民生实事HPV 疫苗第1剂，可继续使用该疫苗完成全程接种。目前第1剂接种已结束。未接种过民生实事疫苗且符合国 家免疫规划接种条件的适龄女生，可选择国家免疫规划HPV疫苗进行接种。 本报讯（记者 孙乐琪）市疾控局昨天介绍，本市已全面启动适龄女生国家免疫规划HPV（人乳头瘤病 毒）疫苗接种，为满13周岁女生免费接种HPV疫苗。 市疾控局介绍，2011年11月10日以后出生的满13周岁女孩可免费接种2剂次双价HPV疫苗，2剂之间的接 种间隔为6个月。如果受种者未按照常规免疫程序完成2剂次疫苗接种，应在18岁之前尽早补齐2剂次。 第2剂与第1剂接种间隔6个月，间隔期最好不要超过一年。 适龄女生可根据所在学校安排，参加校内集中接种，也可通过拨打预防接种门诊电话、现场登记、"京 通"小程序、"首都疫苗服务" App等方式预约。预防接种门诊信 ...

（来源：中国妇女报） 转自：中国妇女报 新华社发 徐骏/作 10月30日，国家疾控局、国家卫生健康委、教育部、国务院妇儿工委办公室等7部门联合发布《关于将 人乳头瘤病毒疫苗纳入国家免疫规划有关工作事宜的通知》，决定自2025年11月10日起，将HPV疫苗纳 入国家免疫规划，组织各地为2011年11月10日以后出生的满13周岁女孩免费接种2剂次双价HPV疫苗。 切实降低HPV感染所致宫颈癌等疾病负担，这不仅是降低我国宫颈癌疾病家庭负担的关键一步，更是推 动全民健康的国家承诺。 ...

Group 1 - The core point of the article is that the HPV vaccine has been officially included in the national immunization program, allowing eligible girls to receive free vaccination services [3][4]. Group 2 - The target population for the HPV vaccine includes girls who are 13 years old and above, specifically those born after November 10, 2011 [4]. - Eligible individuals can receive two doses of the bivalent HPV vaccine for free, with the second dose administered six months after the first, and the interval should not exceed one year [5]. - The vaccination can be administered simultaneously with other vaccines at different injection sites [5]. Group 3 - Important considerations for vaccination include the requirement for a guardian to accompany the child, bringing identification documents, and monitoring for 30 minutes post-vaccination for any adverse reactions [5].

Core Points - The National Health Commission and six other departments announced the inclusion of the HPV vaccine in the national immunization program starting November 10, 2025, providing free vaccinations for girls born after November 10, 2011, who are at least 13 weeks old [1] - Cervical cancer is a common malignant tumor among women, posing significant health risks, and the government has initiated a plan to accelerate the elimination of cervical cancer from 2023 to 2030 [1] - Currently, 18 provinces have implemented policies to provide free HPV vaccinations or subsidies for eligible girls, laying a practical foundation for the national inclusion of the HPV vaccine [1]

Group 1 - The Chinese government has decided to include the HPV vaccine in the national immunization program starting from November 10, 2025, targeting girls born after November 10, 2011, who are 13 years old, providing them with two doses of the bivalent HPV vaccine for free [1][2] - The decision is based on the rising incidence and mortality rates of cervical cancer in China, particularly among younger populations, highlighting the importance of HPV vaccination in preventing high-risk HPV infections and reducing the occurrence of cervical cancer [1][2] - The World Health Organization recommends vaccinating girls aged 9 to 14 years before they become sexually active, while China has set the target group for free vaccination at 13 years old, considering the optimal balance of protection effectiveness, cost-effectiveness, and operational feasibility [1][2] Group 2 - The notification emphasizes the need for monitoring the production and supply of HPV vaccines, with various departments responsible for ensuring stable production and addressing challenges faced by manufacturers [2] - China has a total annual production capacity of 55 million doses of the bivalent HPV vaccine from two domestic manufacturers, which is sufficient to meet market demand, and these vaccines have received pre-certification from the World Health Organization [2] - The first domestically produced nine-valent HPV vaccine was approved for market use in mid-2023, marking it as the second nine-valent HPV vaccine globally and breaking the long-standing market monopoly held by foreign products [2]

Group 1 - The inclusion of the HPV vaccine in the national immunization program is a significant step towards reducing the burden of cervical cancer in China and promoting public health [4][5] - The target population for the free vaccination program is girls aged 13 years and older, who will receive two doses of the bivalent HPV vaccine, with a six-month interval between doses [4] - In 2022, approximately 151,000 new cases of cervical cancer were reported in China, with around 56,000 deaths, highlighting the urgency of preventive measures [4] Group 2 - The domestic production capacity for the bivalent HPV vaccine is 55 million doses annually, sufficient to meet market demand, and both manufacturers have received pre-certification from the World Health Organization [5] - The initiative to include the HPV vaccine in the national immunization program represents a new phase in China's immunization efforts, aiming to enhance health equity and accessibility [5] - The collaboration among various departments is essential to ensure the smooth implementation of the vaccination policy, which aims to protect more girls from cervical cancer [5]

Core Points - The Chinese government has committed to providing free HPV vaccinations for girls aged 13 and above, starting from November 10, 2025, as part of the national immunization program [1][2] - This initiative aims to reduce the financial burden of cervical cancer on families and promote public health [1] - Cervical cancer is a significant health threat to women, with approximately 151,000 new cases and 56,000 deaths reported in China in 2022 [1] Group 1 - The policy will allow eligible girls to receive two doses of the bivalent HPV vaccine for free, with a six-month interval between doses [2] - The initiative is designed to improve vaccination rates and ensure equitable access across different regions and income groups [2] - The decision to target 13-year-old girls is based on considerations of protection effectiveness, cost-effectiveness, and operational feasibility [2] Group 2 - The domestic production capacity for the bivalent HPV vaccine is 55 million doses annually, sufficient to meet market demand [3] - The inclusion of the HPV vaccine in the national immunization program marks a new phase in China's immunization efforts [3] - The initiative reflects China's commitment to women's health and aims to contribute to global health equity [3]

Core Points - The Chinese government has included the human papillomavirus (HPV) vaccine in the national immunization program [3] - Girls born after November 10, 2011, who are 13 years old or older, can receive two doses of the bivalent HPV vaccine for free [2][3] - The bivalent HPV vaccine targets the 16 and 18 genotypes of the virus and is administered with a six-month interval between doses [3] Summary by Category - **Government Policy** - The inclusion of the HPV vaccine in the national immunization program is approved by the State Council [3] - **Target Population** - The program specifically targets girls who were born after November 10, 2011, and are at least 13 years old [2][3] - **Vaccine Details** - The vaccine provided is a bivalent type, focusing on genotypes 16 and 18, with a recommended administration schedule of two doses spaced six months apart [3]

Group 1 - The core viewpoint is that the HPV vaccine has been included in the national immunization program in China, allowing for free vaccination for eligible girls [4] - The vaccine is specifically targeted at girls born after November 10, 2011, who are 13 years old or older, and they can receive two doses of the bivalent HPV vaccine for free [2][4] - The vaccination will cover the HPV types 16 and 18, which are known to be associated with cervical cancer [4] Group 2 - The vaccination will be administered in two doses with a six-month interval between them [4] - This initiative is part of the government's efforts to enhance public health and prevent HPV-related diseases [4]

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program represents a significant commitment to women's health in China, aiming to reduce the burden of cervical cancer and promote public health [4][7]. Group 1: HPV Vaccine Implementation - The HPV vaccine will be available for free to girls who turn 13 years old after November 10, 2011, starting from November 10, 2025, with a total of two doses administered six months apart [4]. - In 2022, there were approximately 151,000 new cases of cervical cancer and about 56,000 deaths in China, highlighting the urgent need for preventive measures [4]. - The initiative aims to improve vaccination rates and reduce disparities in access among different regions and income groups, ensuring equitable health services for the target population [4][6]. Group 2: Immunization Effectiveness - Vaccinating girls at the age of 13 is expected to yield higher antibody levels and more durable protection against HPV [5]. - The decision to target 13-year-old girls for free vaccination is based on considerations of effectiveness, cost-benefit, and operational feasibility [4]. Group 3: Vaccine Production and Capacity - The domestic production of the bivalent HPV vaccine is handled by two companies, with an annual production capacity of 55 million doses, sufficient to meet market demand [6]. - All vaccines produced have received pre-certification from the World Health Organization, ensuring their quality and safety [6]. Group 4: Broader Health Impact - The inclusion of the HPV vaccine in the national immunization program marks a new phase in China's immunization efforts, contributing to global health equity [7]. - The initiative involves collaboration across multiple departments to ensure smooth implementation and effective monitoring of vaccination and associated risks [7].